Jeil Pharma Holdings Inc (KRX:002620)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,350.00
-40.00 (-0.54%)
Last updated: Jun 4, 2026, 3:00 PM KST

Jeil Pharma Holdings Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
13,44114,635-51,159-16,250-74,556-3,482
Depreciation & Amortization
15,05914,94914,09912,55610,9058,983
Loss (Gain) From Sale of Assets
-8.88-12.08-7.97-0.53-23.98-1,930
Asset Writedown & Restructuring Costs
--45,20428,60478,33516,388
Loss (Gain) From Sale of Investments
-5,184-5,175-5,586-2,916-6,271-20,857
Loss (Gain) on Equity Investments
-26,282-24,722-9,855-9,329-5,708-8,452
Stock-Based Compensation
599.05696.531,026578.03472.48163.17
Provision & Write-off of Bad Debts
392558.49-682.67-2,423-308.411,669
Other Operating Activities
34,94928,90026,15113,3092,0146,516
Change in Accounts Receivable
32,12626,816-11,223-14,328-12,72210,835
Change in Inventory
-1,4084,868-3,266-12,1701,3479,341
Change in Accounts Payable
-49,386-50,188-7,721-9,8493,35810,024
Change in Other Net Operating Assets
-2,401-10,9367,5637,803-14,098-15,795
Operating Cash Flow
11,896390.264,542-4,416-17,25613,403
Operating Cash Flow Growth
--91.41%----
Capital Expenditures
-9,427-8,283-4,340-6,223-15,462-23,688
Sale of Property, Plant & Equipment
58.1412.28.3587.6423.9837,800
Sale (Purchase) of Intangibles
-1,054-1,045-2,523-3,571-5,94891.43
Investment in Securities
-7,158-5,3128,508-3,770169.41-10,506
Other Investing Activities
-0-0620.4351.01106.463,627
Investing Cash Flow
-17,581-14,6282,274-13,425-21,1107,325
Short-Term Debt Issued
-24,11513,84325,83427,163-
Long-Term Debt Issued
-5,000---12,288
Total Debt Issued
28,53829,11513,84325,83427,16312,288
Short-Term Debt Repaid
--16,500-13,000---42,477
Long-Term Debt Repaid
--938-5,254-4,084-6,377-7,146
Total Debt Repaid
-21,529-17,438-18,254-4,084-6,377-49,623
Net Debt Issued (Repaid)
7,00811,677-4,41121,75020,785-37,335
Issuance of Common Stock
3,191----7,498
Repurchase of Common Stock
-----396.98-810.02
Dividends Paid
-183.17-183.17-1,134-1,134-1,475-1,590
Other Financing Activities
-489.25-280.7219,762-026,00120,000
Financing Cash Flow
9,52711,21314,21720,61644,914-12,238
Foreign Exchange Rate Adjustments
-136.57-607.381,749-496.29-369.37-93.19
Net Cash Flow
3,705-3,63122,7822,2796,1798,397
Free Cash Flow
2,469-7,893202.38-10,638-32,717-10,284
Free Cash Flow Margin
0.39%-1.20%0.03%-1.32%-4.13%-1.35%
Free Cash Flow Per Share
160.81-514.1813.19-692.99-2131.27-669.95
Cash Interest Paid
7,6137,5938,0519,0444,8912,592
Cash Income Tax Paid
11,9119,0933,2892,092-596.655,401
Levered Free Cash Flow
5,2002,34111,675-19,889-20,2307,866
Unlevered Free Cash Flow
9,8617,02517,221-13,219-16,5109,921
Change in Working Capital
-21,068-29,439-14,647-28,544-22,11514,405